Home / Resource Library / Pirtobrutinib vs ibrutinib in treatment-naive and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
Pirtobrutinib vs ibrutinib in treatment-naive and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor